DIA Biosimilars 2013

Awards & Advancement

Pulmatrix appoints Robert Clarke as CEO

Thursday, September 6, 2012 08:28 AM

Pulmatrix, a Lexington, Mass.-based clinical stage biotechnology company, has promoted Robert Clarke, Ph.D., to the position of CEO and to the board of directors.

More... »

Cenduit: Now with Patient Reminders

Codexis appoints David O’Toole as CFO

Wednesday, September 5, 2012 11:08 AM

Codexis, a Redwood City, Calif.-based developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, has appointed David O’Toole as senior vice president and CFO.

More... »

CRF Health – eCOA Forum

RPS appoints Stephen Kasay as CIO

Thursday, August 30, 2012 03:02 PM

ReSearch Pharmaceutical Services (RPS), a Fort Washington, Penn.-based next generation global CRO that provides comprehensive phase I-IV clinical development solutions, has appointed Stephen Kasay as chief information officer.

More... »

Y-Prime names Greef as senior business analyst

Thursday, August 30, 2012 02:53 PM

Y-Prime Technologies, an Malvern, Penn.-based eClinical products and life sciences consulting services company, has expanded its international operations in Europe and has named Jeanette Anne Greef as senior business analyst in the U.K. office.

More... »

Actinium Pharmaceuticals strengthens management team

Thursday, August 30, 2012 02:44 PM

Actinium Pharmaceuticals (API), a private biopharmaceutical company in New York that develops innovative targeted radio-immunotherapeutics, has strengthened its management team with the appointment of Jack V. Talley as president and CEO and Enza Guagenti as CFO.

More... »

New England Biolabs achieves ISO 14001 recertification

Wednesday, August 22, 2012 01:45 PM

New England Biolabs, a producer and supplier reagents for the life science industry has received ISO 14001 recertification in recognition of the company's dedication to and outstanding record of achievement in its Environmental Management Systems (EMS).

More... »

BioMotiv names Shah as new CEO

Tuesday, August 21, 2012 12:23 PM

BioMotiv has appointed of Baiju R. Shah as its new chief executive officer and as a member of its board of managers, effective September 1, 2012. 

More... »

Adventrx names Vetticaden as chief medical officer

Monday, August 20, 2012 04:01 PM

Adventrx Pharmaceuticals, a biopharmaceutical company based in San Diego, has appointed Santosh J. Vetticaden, M.D., Ph.D., as chief medical officer and senior vice president.

More... »

Radiant Sage receives Customer Value Enhancement Award from Frost & Sullivan

Monday, August 20, 2012 03:27 PM

Radiant Sage, a provider of on-demand clinical trial image management solutions based in Belmont, Mass., has received the Frost & Sullivan 2012 Customer Value Enhancement Award for its clinical trial image management solutions.

More... »

Astellas Pharma Europe appoints Wood as senior director, market access

Monday, August 20, 2012 03:21 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Dr, Susan Wood as senior director, market access.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs